Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids

• Published in: International journal of nanomedicine 2021, Vol.16, p.2965-2981
• Main Authors: Palzer, Julian, Mues, Benedikt, Goerg, Richard, Aberle, Merel, Rensen, Sander S, Olde Damink, Steven W M, Vaes, Rianne D W, Cramer, Thorsten, Schmitz-Rode, Thomas, Neumann, Ulf P, Slabu, Ioana, Roeth, Anjali A
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - pathology; Adenocarcinoma - therapy; Biocompatibility; Cancer; Cancer therapies; Carcinoma, Pancreatic Ductal - metabolism; Carcinoma, Pancreatic Ductal - pathology; Cell culture; Cell Death; Cell Line, Tumor; Cell Survival; Chemotherapy; Clone Cells; Drug therapy; Efficiency; Ferric oxide; Fever; Humans; Hyperthermia; Hyperthermia, Induced; Magnetic fields; magnetic fluid hyperthermia; magnetic nanoparticles; Magnetic Phenomena; Medical prognosis; Nanoparticles; organoids; Organoids - pathology; Original Research; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; pdac; Prognosis; spion; Tumors
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/ijn.s288379

Pancreatic ductal adenocarcinoma (PDAC) is a cancer with a meager prognosis due to its chemotherapy resistance. A new treatment method may be magnetic fluid hyperthermia (MFH). Magnetoliposomes (ML), consisting of superparamagnetic iron oxide nanoparticles (SPION) stabilized with a phospholipid-bilayer, are exposed to an alternating magnetic field (AMF) to generate heat. To optimize this therapy, we investigated the effects of MFH on human PDAC cell lines and 3D organoid cultures. ML cytotoxicity was tested on Mia PaCa-2 and PANC-1 cells and on PDAC 3D organoid cultures, generated from resected tissue of patients. The MFH was achieved by AMF application with an amplitude of 40-47 kA/m and a frequency of 270 kHz. The MFH effect on the cell viability of the cell lines and the organoid cultures was investigated at two different time points. Clonogenic assays evaluated the impairment of colony formation. Altering ML set-ups addressed differences arising from intra- vs extracellular ML locations. Mia PaCa-2 and PANC-1 cells showed no cytotoxic effects at ML concentrations up to 300 µg(Fe)/mL and 225 µg(Fe)/mL, respectively. ML at a concentration of 225 µg(Fe)/mL were also non-toxic for PDAC organoid cultures. MFH treatment using exclusively extracellular ML presented the highest impact on cell viability. Clonogenic assays demonstrated remarkable impairment as long-term outcome in MFH-treated PDAC cell lines. Additionally, we successfully treated PDAC organoids with extracellular ML-derived MFH, resulting in notably reduced cell viabilities 2h and 24 h post treatment. Still, PDAC organoids seem to partly recover from MFH after 24 h as opposed to conventional 2D-cultures. Treatment with MFH strongly diminished pancreatic cancer cell viability in vitro, making it a promising treatment strategy. As organoids resemble the more advanced in vivo conditions better than conventional 2D cell lines, our organoid model holds great potential for further investigations.